Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company
decoding biology to industrialize drug discovery, today announced
it has successfully screened the Enamine REAL Space chemical
library using its MatchMaker technology, recently acquired from
Cyclica, to predict the protein target(s) for approximately 36
billion chemical compounds. This accomplishment was made possible
by several other enabling discoveries, including the predicted
structures derived from the AlphaFold2 database for more than
15,000 human proteins containing more than 80,000 potential binding
pockets, as well as the Enamine REAL Space, which is reported to be
the world’s largest searchable chemical library comprised of
approximately 36 billion make-on-demand molecules. In total, this
screen digitally evaluated
more than 2.8
quadrillion small molecule-target pairs.
“This achievement represents a significant and exciting step
toward achieving our mission of decoding biology and chemistry,”
said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion. “Until
this point, the groundbreaking progress across biology and
chemistry that enabled this moment – namely, AlphaFold, the Enamine
virtual chemical library and the rapid advancement of large-scale
compute and new machine learning approaches – have largely lived in
isolation of one another or have been bridged at relatively small
scales. Leveraging Recursion’s machine learning and computational
expertise and NVIDIA’s technology, we have layered these advances
together to predict how each of the molecules in this vast chemical
universe may interact with the protein universe.”
The company generated this massive new data layer of predicted
interactions in less than 90 days after closing the acquisition of
Cyclica and in under 30 days since initiating the collaboration
with NVIDIA.
MatchMaker uses machine learning to assess whether a small
molecule is compatible with a specific protein binding pocket,
providing a solution that is significantly less computationally
intensive and much more scalable than traditional docking and
physics-based interaction simulations. Similar to Recursion’s
phenomics platform, the scalability of MatchMaker enables a
“high-dimensional” view of biochemistry: activity is predicted not
just for a single target, but for many at the same time. This
enables three core advantages: First, this predicted data layer can
be used to determine which wet-lab experiments should be executed
to advance programs faster across a wide range of targets and
chemical space. Second, this predicted data layer can be used as
part of Recursion’s multi-modal dataset to better understand
biological activity across programs quickly and at scale. Finally,
this approach can pre-screen for more computationally expensive
precision modeling techniques implemented by Recursion’s
computational and digital chemistry teams, to more efficiently
advance programs.
“We are excited to collaborate with Recursion to explore the
chemical space and support our mission to accelerate drug
discovery,” said Andrey Tolmachev, Ph.D., Founder and Owner of
Enamine. He continued: “This achievement in the 36 Billion REAL
Space is just a start of our journey. The chemical knowledge
accumulated at Enamine over its 35-years history allows us to
explore trillions of relationships without compromising the high
success rate of synthesis. We believe the predictions made by
Recursion can help us prioritize parts of the chemical universe and
provide an opportunity to develop focused chemical spaces and novel
compounds around discovered hits quickly.”
Much of the initial testing and infrastructure development for
the project was completed using BioHive-1, Recursion’s in-house
supercomputer, an NVIDIA DGX SuperPOD, which is ranked among the
top 125 most powerful supercomputers in the world across any
industry by TOP500 as of June 2023. The final analysis was made
possible by NVIDIA’s DGX Cloud, an advanced
AI-training-as-a-service solution to which Recursion gained access
following its recently announced collaboration with NVIDIA.
Recursion worked with urgency to make this effort happen in a short
period of time.
“Bringing together powerful data, AI and data-center scale
compute, Recursion’s MatchMaker running on NVIDIA DGX Cloud
essentially created a time machine for the company’s drug discovery
program and sets a new bar for the industry,” said Kimberly Powell,
Vice President of Healthcare at NVIDIA. “Within one week, the
Recursion team was able to achieve what would have otherwise taken
100,000 years to compute with physics-based methods — setting the
stage for a wet-lab, dry-lab flywheel to better predict drug-target
interactions and increase a drug’s probability of success in the
clinic.”
Recursion plans to leverage this new database of predictions to
industrialize its chemistry operations across its pipeline and in
service to its partners, enabling significantly greater efficiency
in its medicinal chemistry cycles. Further, Recursion plans to
continue improving and expanding the number and type of chemical
properties and interactions it can predict using in-house tools,
tools acquired through the acquisition of Cyclica, and tools being
developed by Valence Labs, the semi-autonomous research hub powered
by Recursion and formed through the acquisition of Valence
Discovery.
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company
leading the space by decoding biology to industrialize drug
discovery. Enabling its mission is the Recursion OS, a platform
built across diverse technologies that continuously expands one of
the world’s largest proprietary biological and chemical datasets.
Recursion leverages sophisticated machine-learning algorithms to
distill from its dataset a collection of trillions of searchable
relationships across biology and chemistry unconstrained by human
bias. By commanding massive experimental scale — up to millions of
wet lab experiments weekly — and massive computational scale —
owning and operating one of the most powerful supercomputers in the
world, Recursion is uniting technology, biology, and chemistry to
advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a
founding member of BioHive, the Utah life sciences industry
collective. Recursion also has offices in Toronto, Montréal and the
San Francisco Bay Area. Learn more at www.Recursion.com, or connect
on Twitter and LinkedIn.
About Enamine
Headquartered in Kyiv, Ukraine, Enamine combines a CRO profile
with the production and multilevel supply of innovative screening
libraries, novel building blocks, fragments, and various functional
compounds, including covalent and protein degradation compounds.
The company provides integrated support in early drug discovery,
including biological screening, hit-to-lead, and lead optimization
projects. The major assets of the company are the collection of 4
million screening compounds backed up by 36 billion REAL Compounds
for hit follow-up, and the dynamically growing catalog of over
300,000 building blocks. Enamine offers collaborative expertise to
exclusively design and screen libraries of novel small molecular
weight compounds and fragments.
Forward-Looking Statements
This document contains information that includes or is based
upon "forward-looking statements" within the meaning of the
Securities Litigation Reform Act of 1995, including, without
limitation, those regarding the outcomes and benefits expected from
the NVIDIA partnership and Cyclica and Valence Discovery
acquisitions and the launch of Valence Labs; early and late stage
discovery, preclinical, and clinical programs; licenses and
collaborations; prospective products and their potential future
indications and market opportunities; the Recursion OS and other
technologies, including MatchMaker, the Enamine REAL Space chemical
library and NVIDIA’s DGX Cloud; business and financial plans and
performance; and all other statements that are not historical
facts. Forward-looking statements may or may not include
identifying words such as "plan," "will," "expect," "anticipate,"
"intend," "believe," "potential," "continue," and similar terms.
These statements are subject to known or unknown risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied in such statements, including but
not limited to: challenges inherent in pharmaceutical research and
development, including the timing and results of preclinical and
clinical programs, where the risk of failure is high and failure
can occur at any stage prior to or after regulatory approval due to
lack of sufficient efficacy, safety considerations, or other
factors; our ability to leverage and enhance our drug discovery
platform; our ability to obtain financing for development
activities and other corporate purposes; the success of our
collaboration activities; our ability to obtain regulatory approval
of, and ultimately commercialize, drug candidates; our ability to
obtain, maintain, and enforce intellectual property protections;
cyberattacks or other disruptions to our technology systems; our
ability to attract, motivate, and retain key employees and manage
our growth; and other risks and uncertainties such as those
described under the heading "Risk Factors" in our filings with the
U.S. Securities and Exchange Commission, including our most recent
Quarterly Report on Form 10-Q and our Annual Report on Form 10-K.
All forward-looking statements are based on management's current
estimates, projections, and assumptions, and Recursion undertakes
no obligation to correct or update any such statements, whether as
a result of new information, future developments, or otherwise,
except to the extent required by applicable law.
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
Recursion Pharmaceuticals (NASDAQ:RXRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Recursion Pharmaceuticals (NASDAQ:RXRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024